FDA approves Rocket's gene therapy Kresladi for rare immune disorder

Rocket Pharmaceuticals has received accelerated FDA approval for Kresladi (marnetegragene autotemcel), its first hematopoietic stem cell-based gene therapy, to treat children with severe leukocyte adhesion deficiency-1 (LAD-1).